| 2025年年报 | 2025年三季报 | 2025年中报 | 2024年年报 | 2024年中报 | |
|---|---|---|---|---|---|
| 营业收入(元) | |||||
| 分部间抵销(元) | - | - | -63,460,400.00 | - | -55,448,800.00 |
| 输液产品(元) | - | - | 1,491,544,900.00 | - | 1,786,359,600.00 |
| 制剂药品(不含大输液)(元) | - | - | 4,313,425,300.00 | - | 4,198,180,000.00 |
| 慢病业务平台(元) | 3,252,281,578.17 | 2,511,098,500.00 | - | 3,281,490,897.76 | - |
| 输液业务平台(元) | 2,533,300,255.47 | 1,939,287,500.00 | - | 3,036,307,548.94 | - |
| 原料药(元) | - | 930,704,900.00 | - | 1,189,930,974.28 | - |
| 专科业务平台(元) | 3,045,984,905.31 | 2,254,680,100.00 | - | 2,761,565,459.38 | - |
| 原料药业务平台(元) | 1,261,040,541.60 | - | - | - | - |
| 其他(元) | 788,646,882.38 | 569,156,300.00 | - | 849,564,000.09 | - |
| 营业成本(元) | |||||
| 分部间抵销(元) | - | - | -63,247,900.00 | - | -54,843,000.00 |
| 输液产品(元) | - | - | 721,180,100.00 | - | 819,246,300.00 |
| 制剂药品(不含大输液)(元) | - | - | 1,650,084,400.00 | - | 1,696,471,700.00 |
| 慢病业务平台(元) | 873,197,269.14 | 650,131,200.00 | - | 773,844,729.30 | - |
| 输液业务平台(元) | 1,233,118,194.43 | 933,286,800.00 | - | 1,391,458,536.69 | - |
| 原料药(元) | - | 795,182,400.00 | - | 1,122,563,231.13 | - |
| 专科业务平台(元) | 860,876,446.23 | 593,632,700.00 | - | 829,589,388.27 | - |
| 原料药业务平台(元) | 1,080,735,317.47 | - | - | - | - |
| 其他(元) | 524,913,373.32 | 371,029,400.00 | - | 637,018,345.93 | - |
| 毛利(元) | |||||
| 分部间抵销(元) | - | - | -212,500.00 | - | -605,800.00 |
| 输液产品(元) | - | - | 770,364,800.00 | - | 967,113,300.00 |
| 制剂药品(不含大输液)(元) | - | - | 2,663,340,900.00 | - | 2,501,708,300.00 |
| 慢病业务平台(元) | 2,379,084,309.03 | 1,860,967,300.00 | - | 2,507,646,168.46 | - |
| 输液业务平台(元) | 1,300,182,061.04 | 1,006,000,700.00 | - | 1,644,849,012.25 | - |
| 原料药(元) | - | 135,522,500.00 | - | 67,367,743.15 | - |
| 专科业务平台(元) | 2,185,108,459.08 | 1,661,047,400.00 | - | 1,931,976,071.11 | - |
| 原料药业务平台(元) | 180,305,224.13 | - | - | - | - |
| 其他(元) | 263,733,509.06 | 198,126,900.00 | - | 212,545,654.16 | - |
| 毛利率(%) | |||||
| 分部间抵销(%) | - | - | 0.33 | - | 1.09 |
| 输液产品(%) | - | - | 51.65 | - | 54.14 |
| 制剂药品(不含大输液)(%) | - | - | 61.75 | - | 59.59 |
| 慢病业务平台(%) | 73.15 | 74.11 | - | 76.42 | - |
| 输液业务平台(%) | 51.32 | 51.87 | - | 54.17 | - |
| 原料药(%) | - | 14.56 | - | 5.66 | - |
| 专科业务平台(%) | 71.74 | 73.67 | - | 69.96 | - |
| 原料药业务平台(%) | 14.30 | - | - | - | - |
| 其他(%) | 33.44 | 34.81 | - | 25.02 | - |
| 收入构成(%) | |||||
| 分部间抵销(%) | - | - | -1.11 | - | -0.94 |
| 输液产品(%) | - | - | 25.98 | - | 30.13 |
| 制剂药品(不含大输液)(%) | - | - | 75.13 | - | 70.81 |
| 慢病业务平台(%) | 29.89 | 30.60 | - | 29.51 | - |
| 输液业务平台(%) | 23.28 | 23.64 | - | 27.31 | - |
| 原料药(%) | - | 11.34 | - | 10.70 | - |
| 专科业务平台(%) | 27.99 | 27.48 | - | 24.84 | - |
| 原料药业务平台(%) | 11.59 | - | - | - | - |
| 其他(%) | 7.25 | 6.94 | - | 7.64 | - |
| 毛利构成(%) | |||||
| 分部间抵销(%) | - | - | -0.01 | - | -0.02 |
| 输液产品(%) | - | - | 22.44 | - | 27.89 |
| 制剂药品(不含大输液)(%) | - | - | 77.57 | - | 72.13 |
| 慢病业务平台(%) | 37.71 | 38.28 | - | 39.40 | - |
| 输液业务平台(%) | 20.61 | 20.69 | - | 25.84 | - |
| 原料药(%) | - | 2.79 | - | 1.06 | - |
| 专科业务平台(%) | 34.64 | 34.17 | - | 30.36 | - |
| 原料药业务平台(%) | 2.86 | - | - | - | - |
| 其他(%) | 4.18 | 4.08 | - | 3.34 | - |